Biogen to Acquire Vigil Neuroscience for $7.30/share + CVR
| Field | Detail |
|---|---|
| Company | Vigil Neuroscience, Inc. |
| Form Type | 8-K |
| Filed Date | Jul 28, 2025 |
| Risk Level | medium |
| Sentiment | bullish |
Sentiment: bullish
Topics: acquisition, biotech, merger
Related Tickers: BIIB
TL;DR
Biogen buying Vigil for $7.30 cash + CVR, deal expected H2 2025.
AI Summary
Vigil Neuroscience, Inc. announced on July 28, 2025, that it has entered into a definitive agreement to be acquired by Biogen Inc. for $7.30 per share in cash, plus a potential CVR for an additional $2.00 per share. This transaction is expected to close in the second half of 2025, subject to customary closing conditions.
Why It Matters
This acquisition by Biogen, a major player in the neuroscience field, could significantly advance the development of Vigil's investigational therapies for rare neurodegenerative diseases.
Risk Assessment
Risk Level: medium — The acquisition is subject to customary closing conditions, including regulatory approvals, which could delay or prevent the deal from closing.
Key Numbers
- $7.30 — Acquisition Price per Share (Base cash consideration offered by Biogen.)
- $2.00 — Potential CVR Value (Additional payment contingent on future milestones.)
Key Players & Entities
- Vigil Neuroscience, Inc. (company) — Registrant
- Biogen Inc. (company) — Acquiring company
- $7.30 (dollar_amount) — Cash purchase price per share
- $2.00 (dollar_amount) — Potential CVR value per share
- July 28, 2025 (date) — Date of report and agreement
- second half of 2025 (date) — Expected closing period
FAQ
What is the total potential value of the acquisition per share?
The total potential value per share is $9.30, consisting of $7.30 in cash plus a potential $2.00 in a CVR.
Who is acquiring Vigil Neuroscience?
Biogen Inc. is acquiring Vigil Neuroscience.
When is the acquisition expected to close?
The acquisition is expected to close in the second half of 2025.
What is the primary business of Vigil Neuroscience?
Vigil Neuroscience is focused on developing treatments for rare neurodegenerative diseases.
What are the conditions for the acquisition to close?
The acquisition is subject to customary closing conditions, which typically include regulatory approvals.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 28, 2025 regarding Vigil Neuroscience, Inc..